jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Dec. 09, 2024

June. 26, 2025

jRCTs032240534

Randomized parallel group trial of prophylactic compression therapy for chemotherapy-induced peripheral neuropathy (COMPLET Study)

A randomized controlled trial compression therapy for CIPN (COMPLET Study)

Bando Hiroko

University of Tsukuba Hospital

2-1-1 Amakubo,Tsukuba,Ibaraki

+81-29-853-3341

bando@md.tsukuba.ac.jp

Bando Hiroko

University of Tsukuba Hospital

2-1-1 Amakubo,Tsukuba,Ibaraki

+81-29-853-3341

bando@md.tsukuba.ac.jp

Recruiting

Dec. 09, 2024

Mar. 04, 2025
120

Interventional

randomized controlled trial

open(masking not used)

no treatment control/standard of care control

parallel assignment

prevention purpose

(1) Patients aged between 18 and 75 at the time of consent
(2) Patients with. Stage1-3C primary breast cancer
(3) Patients receiving taxane anticancer drugs in perioperative chemotherapy for primary breast cancer
(4) Eastern Cooperative Oncoligy Group Performance Status 0 or 1
(5) Patients who can adequately answer patient questionnaires
(6) Patients who understand this study and given writien consent to participate in this study

(1) Patients with CTCAE version 5.0 Grade2 or more peripheral neuropathy in the upper or lower limbs
(2) Patients with arterial blood circulation disorders such asa arteriosclerosis obliterans
(3) Patients with infectious or inflammatory diseases on the skin aroung the upper and lower limbs
(4) Patients diagnosed with acute or painful deep vein thrombosis within one year of screening
(5) Patients with severe congestive heart failure
(6)Patients with allergies to the compression gloves or stockings used in this study
(7) Patients of extremely small or large hands that deviate from the size range of elastic gloves
(8) Patients of extremely small or large lower limbs that deviate from the range of medical compression stocings
(9) Patients with thrombophlebitis of the superficial veins of the lower extremeties
(10) Other patients that the research doctor deems i nappropriate

18age old over
75age old not

Female

Primary breast cancer

Participants in the intervention group:
Compression therapy of hands and lower limbs is performed from 15 minutes before administration of taxane to 15 minutes after the end of administration
Compression therapy of hands: Wearing elastic gloves on both hands
Compression therapy of lower limbs: Wearing two layers of elastic stockings on each lower limbs

Control group: Aggressive supportive care

Incidence of peripheral neuropathy of the lower limbs of CTCAE version 5.0 Grade2 or higher at the end of four cycles of perioperative chemotherapy with taxane anticancer drugs

1. Incidence of peripheral neuropathy in the hands (CTCAEv5.0 grade 2 or higher) at the end of perioperative chemotherapy using taxane anticancer drugs
2. Assessment of CIPN in the hands and lower limbs using the Patient Neurotoxicity Questionnaire (PNQ)
3. Time to onset of CIPN in the hands and lower limbs (CTCAe v5.0 Grade 2 or higher)
4. Subjective symptoms of CIPN based on patient diary PRO-CTCAE TM Japanese version
5. Grip strength
6. Evaluation of CIPN onset using vibration sense (bilateral medial malleolus, Rydel-Seiffer tuning fork)
7. Changes in PainVision scores for hands and lower limbs
8. Evaluation of chemotherapy-induced skin disorders of the hands and lower limbs using CTCAEv5.0
9. Assessment of edema by changes in hands and lower limbs circumference
10. Completion rate of compression therapy
11. Relative Dose Intensity of Taxanes
12. Correlation between compression pressure and incidence of CIPN
13. Adverse events of compression therapy

University of Tsukuba Hospital
Not applicable
Japan Society for the Promotion of Science
Not applicable
University of Tsukuba Clinical Research Review Board
1-1-1Tennodai, Tsukuba, Ibaraki, Ibaraki

+81-29-853-3749

tcr.nintei@un.tsukuba.ac.jp
Approval

Nov. 27, 2024

No

none

History of Changes

No Publication date
7 June. 26, 2025 (this page) Changes
6 Mar. 31, 2025 Detail Changes
5 Mar. 11, 2025 Detail Changes
4 Mar. 06, 2025 Detail Changes
3 Feb. 26, 2025 Detail Changes
2 Jan. 14, 2025 Detail Changes
1 Dec. 09, 2024 Detail